Therapeutic target
- Acid inhibition
Therapy recommendations
- Proton pump inhibitors (first-line agent).
- H2 antihistamines (second-line agents).
- Octreotide (to reduce gastrin secretion).
- See also under “Other therapy.”
Further notes
- Red Hand Letter on Ranitidine dated 08/11/2019: Daily doses up to 900 mg exceed the daily limit of N-nitrosodimethylamine (NDMA), which is a probable carcinogen.
